Michael Charlton to Protein Kinase Inhibitors
This is a "connection" page, showing publications Michael Charlton has written about Protein Kinase Inhibitors.
Connection Strength
0.140
-
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559.
Score: 0.115
-
Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterology. 2016 Apr; 150(4):956-67.
Score: 0.025